PFIZER INC

PFE Healthcare & Pharma 5/10 Medium Risk
5/10

PFIZER INC has $4.0B in total long-term debt with $31.4B in scheduled maturities. Overall, PFE carries moderate refinancing risk (score 5/10).

Maturity Schedule

Year 1 $0 Year 2 $3.6B Year 3 $3.4B Year 4 $360M Year 5 $4.2B Beyond 5 $19.9B
Period Amount Due % of Total
Year 1 (0-12 months) N/A N/A
Year 2 (12-24 months) $3.6B 11.4%
Year 3 (24-36 months) $3.4B 10.7%
Year 4 (36-48 months) $360M 1.1%
Year 5 (48-60 months) $4.2B 13.5%
Beyond 5 Years $19.9B 63.3%
Total Scheduled Maturities $31.4B 100.0%

Key Metrics

Total Long-Term Debt
$4.0B
Near-Term (12mo)
N/A
Interest Coverage
N/A
Debt/Equity
0.05
Cash Coverage
0.15x
Operating Income
N/A

Score Components

Component Value Weight
Near-Term Maturity Concentration N/A 30%
Interest Coverage Ratio N/A 25%
Debt-to-Equity Ratio 0.05 25%
Cash Coverage of Near-Term Debt 0.15x 20%

Related Companies

JOHNSON & JOHNSON
JNJ
1/10
Debt: $32.4B 12mo: $2.0B
AbbVie Inc.
ABBV
5/10
Debt: $64.5B 12mo: $6.0B
Merck & Co., Inc.
MRK
3/10
Debt: N/A 12mo: $2.6B
ELI LILLY & Co
LLY
3/10
Debt: $19.1B 12mo: $781M
BRISTOL MYERS SQUIBB CO
BMY
4/10
Debt: $49.4B 12mo: $2.0B
AMGEN INC
AMGN
5/10
Debt: $60.1B 12mo: $4.6B
GILEAD SCIENCES, INC.
GILD
4/10
Debt: $26.7B 12mo: $2.8B
REGENERON PHARMACEUTICALS, INC.
REGN
1/10
Debt: N/A 12mo: N/A

Data Source: Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports). Most recent filing date: 2026-02-26. Data last fetched: 2026-03-15. Maturity schedules reflect the company's most recently reported debt repayment obligations. Data quality: Partial.